← Leaderboards
Vincent Charles Marconi
Veterans Health Administration
$11,562,796
Attributed
$29,304,200
Total exposure
9
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.3M · FY2013–25$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,304,200 · 7
VA$0 · 2
By mechanism
R01$24,456,536 · 5
UH3$3,190,246 · 1
UG3$1,657,418 · 1
I01$0 · 2
Top collaborators
- Yan Sun7 shared
- Mohammed Kumail Ali6 shared
- Francois Venter6 shared
- Daniel R Kuritzkes5 shared
- Krisann K Oursler5 shared
- Mirko Paiardini5 shared
- Alice S. Ryan5 shared
- Christina Gavegnano3 shared
Most similar at Veterans Health Administration
Same institution · by research overlap
- Mervyn Neale Weitzmann$11,173,484
- Daniel E Forman$10,507,614
- Alvin Carter Powers$48,377,762
- Kamyar Kalantar-Zadeh$11,734,421
- Edith Tzeng$11,643,874
Others in their field
Top investigators on “Antiretroviral Therapy”
- James Dennis Neaton · Northwestern University$279,044,427
- Lawrence Corey · Fred Hutchinson Cancer Center$278,220,635
- Constance Ann Benson · University Of California, San Diego$241,336,455
- Carol Nesel · Westat$188,148,170
- Judith S. Currier · University Of California Los Angeles$182,467,520
- Barbara Driver · Westat, Inc.$170,789,549
Research focus
Antiretroviral TherapyDesignSiteHiv InfectionsAffectPersonsMolecularComorbidityInnovationRisk FactorsInfectionLinkMortalityResponseCaringPathway InteractionsAcquired Immunodeficiency SyndromeDiabetes MellitusModificationCostMorbidity - Disease RateSuccessImmune ResponseEpigenetic Marker
Grant awards (36)
REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD$6,107,805
R01 · FY2025 · AG
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system$638,381
R01 · FY2025 · MH
Host Genetic and Epigenetic Factors of the Progression, Comorbidities and Outcomes of Viral Infection$0
I01 · FY2025 · VA · contact PI
REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD$5,665,215
R01 · FY2024 · AG
Integrating HIV and hEART health in South Africa (iHeart-SA)$1,218,970
UH3 · FY2024 · HL
Multi-omic Predictors of Renal Function among HIV-infected Individuals of African Ancestry$730,203
R01 · FY2024 · DK
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system$638,381
R01 · FY2024 · MH
Host Genetic and Epigenetic Factors of the Progression, Comorbidities and Outcomes of Viral Infection$0
I01 · FY2024 · VA · contact PI
Integrating HIV and hEART health in South Africa (iHeart-SA)$835,818
UH3 · FY2023 · HL
Multi-omic Predictors of Renal Function among HIV-infected Individuals of African Ancestry$771,174
R01 · FY2023 · DK
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system$638,381
R01 · FY2023 · MH
Multi-omic Predictors of Renal Function among HIV-infected Individuals of African Ancestry$335,487
R01 · FY2023 · DK
Integrating HIV and hEART health in South Africa (iHeart-SA)$299,997
UH3 · FY2023 · HL
Multi-omic Predictors of Renal Function among HIV-infected Individuals of African Ancestry$100,000
R01 · FY2023 · DK
Effects of 12-weeks of High-intensity Resistance Aerobic Circuit Exercise Training on Epigenetic Aging and Inflammation in Older HIV-infected Veterans$0
I01 · FY2023 · VA
Host Genetic and Epigenetic Factors of the Progression, Comorbidities and Outcomes of Viral Infection$0
I01 · FY2023 · VA · contact PI
Integrating HIV and hEART health in South Africa (iHeart-SA)$835,461
UH3 · FY2022 · HL
Multi-omic Predictors of Renal Function among HIV-infected Individuals of African Ancestry$709,645
R01 · FY2022 · DK
Effects of 12-weeks of High-intensity Resistance Aerobic Circuit Exercise Training on Epigenetic Aging and Inflammation in Older HIV-infected Veterans$0
I01 · FY2022 · VA
Integrating HIV and hEART health in South Africa (iHeart-SA)$858,999
UG3 · FY2021 · HL
Multi-omic Predictors of Renal Function among HIV-infected Individuals of African Ancestry$708,865
R01 · FY2021 · DK
Effects of 12-weeks of High-intensity Resistance Aerobic Circuit Exercise Training on Epigenetic Aging and Inflammation in Older HIV-infected Veterans$0
I01 · FY2021 · VA
Effects of 12-weeks of High-intensity Resistance Aerobic Circuit Exercise Training on Epigenetic Aging and Inflammation in Older HIV-infected Veterans$0
I01 · FY2021 · VA
Integrating HIV and hEART health in South Africa (iHeart-SA)$798,419
UG3 · FY2020 · HL
Multi-omic Predictors of Renal Function among HIV-infected Individuals of African Ancestry$705,254
R01 · FY2020 · DK
Effects of 12-weeks of High-intensity Resistance Aerobic Circuit Exercise Training on Epigenetic Aging and Inflammation in Older HIV-infected Veterans$0
I01 · FY2020 · VA
Central memory CD4 T cell infection: key role in ART response and HIV persistence$853,991
R01 · FY2017 · AI
Antiretroviral drug resistance in KwaZulu Natal$221,602
R01 · FY2017 · AI
Central memory CD4 T cell infection: key role in ART response and HIV persistence$869,119
R01 · FY2016 · AI
Antiretroviral drug resistance in KwaZulu Natal$554,533
R01 · FY2016 · AI
Central memory CD4 T cell infection: key role in ART response and HIV persistence$881,672
R01 · FY2015 · AI
Antiretroviral drug resistance in KwaZulu Natal$567,366
R01 · FY2015 · AI
Central memory CD4 T cell infection: key role in ART response and HIV persistence$895,012
R01 · FY2014 · AI
Antiretroviral drug resistance in KwaZulu Natal$474,296
R01 · FY2014 · AI
Central memory CD4 T cell infection: key role in ART response and HIV persistence$873,611
R01 · FY2013 · AI
Antiretroviral drug resistance in KwaZulu Natal$516,543
R01 · FY2013 · AI